Weekly Paclitaxel Plus Bevacizumab Versus Docetaxel As Second or Third-Line Treatment in Advanced Non-Squamous Non-Small Cell Lung Cancer (nsclc): Results from the Phase Iii Study Ifct-1103 Ultimate.
European Journal of Cancer（2020）
Key words
NSCLC,Paclitaxel,Docetaxel,Bevacizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined